Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
With
Merck Sharp & Dohme LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants must have received a PD-1 PDLI therapy within 9 weeks of starting dosing on this study \[for example, nivolumab, pembrolizumab, atezolizumab\]
Participants must be willing to have tumor biopsies
Participants must have adequate organ function
Participants must have Eastern Cooperative Oncology Group (ECOG) status of 0 or 1
Participants must be able to swallow tablets
Participants with stable, previously treated brain metastases may participate if neurologic symptoms have resolved and participants have been off steroids for at least 14 days
You may not be if
Participants must not have moderate or severe cardiovascular disease
Participants must not have active autoimmune disease (for example Crohn's disease, Hashimotos disease, etc)
Participants must not have an active infection requiring treatment
